share_log

NURO Stock: The ‘Breakthrough’ News Rocketing NeuroMetrix Shares Higher Today

NURO Stock: The ‘Breakthrough’ News Rocketing NeuroMetrix Shares Higher Today

股票资讯:今天neurometrix股票大涨的“突破性”新闻
InvestorPlace ·  2021/07/20 11:03

InvestorPlace - Stock Market News, Stock Advice & Trading Tips

InvestorPlace-股市新闻、股票建议、交易技巧

NeuroMetrix (NASDAQ:NURO) stock is surging higher on Tuesday after getting “Breakthrough Device Designation” from the U.S. Food and Drug Administration (FDA).

NeuroMetrix(纳斯达克:NURO)股票在周二获得美国食品和药物管理局(FDA)的“突破性设备认定”之后,出现了飙升。

Source: Shutterstock
来源:shutterstock

The breakthrough designation is for NeuroMetrix’s Quell device designed to treat symptoms in adult patients suffering from fibromyalgia. This is due to the unmet need for managing pain from fibromyalgia without pharmacological treatments.

这一突破性认证是针对NeuroMetrix的Quell设备,旨在治疗成年患有纤维肌痛症状的患者。这是由于纤维肌痛症的疼痛管理需求未得到药物治疗。

While there are medicines to treat the pain of fibromyalgia, NeuroMetrix seeks to help manage it further with Quell. The device is only the size of a credit card and can connect to the company’s app via Bluetooth to assist with fibromyalgia managment.

虽然有药物可以治疗纤维肌痛的疼痛,但NeuroMetrix希望通过Quell进一步帮助管理它。该设备仅有信用卡大小,并可以通过蓝牙连接到该公司的应用程序,帮助管理纤维肌痛。

It’s worth pointing out that the designation for Quell comes after a clinical trial. This double-blind study saw 119 patients enrolled. Of those on Quell, 56% reported a clinically meaningful improvement in health-related quality-of-life. For comparison, only 35% achieved that in the sham group.

值得指出的是,Quell的认证是在临床试验后获得的。这个双盲研究有119名患者参与。在使用Quell的患者中,56%的人报告了与健康相关的生活质量的临床意义重大的改善。相比之下,假手术组只有35%达到了这个指标。


  • 7 'A-Rated' Small-Cap Stocks to Buy Now

  • 7个'A级'的小市值股票,现在买入

Shai N. Gozani, M.D., Ph.D., president and CEO of NeuroMetrix, had the following to say about the news sending NURO stock higher today.

NeuroMetrix的总裁兼首席执行官Shai N. Gozani博士对今日使NURO股票上涨的消息发表了以下看法。

“The Breakthrough Device Designation is an important milestone in the Company’s effort to make Quell technology available to people living with fibromyalgia. We are moving forward with a regulatory filing that could position us to launch Quell for this indication in the second half of next year.”

“突破性设备认定对于公司努力让Quell技术面向患有纤维肌痛的人群具有重要意义。我们正在推进监管申请,该申请可能使我们能够在明年下半年为该适应症推出Quell。”

To go along with this news, NURO stock is seeing incredibly heavy trading today. As of this writing, more than 37 million shares of the stock have changed hands. That’s quite the increase compared to its daily average trading volume of around 114,000 shares.

除了这一消息外,NURO股票今天的交易量也非常巨大。截至目前,该股股票已经交易超过3700万股,相较于其日均交易量约为11.4万股,这是一个相当大的增长。

NURO stock was up 42.6% as of Tuesday morning.

截至周二上午,NURO股价上涨了42.6%。

Of course, there is more going on with the market today that’s worth looking into.

当然,今天市场上发生了更多值得关注的事情。

Luckily, InvestorPlace has it covered. That includes the latest stock news concerning Peloton (NASDAQ:PTON), Ardelyx (NASDAQ:ARDX), and Nvidia (NASDAQ:NVDA). You can learn all about this at the links below!

幸运的是,“本周加密游戏”栏目就在这里。如果您想要一个快速了解加密游戏最新动态的途径,我们即将推出“本周加密游戏”一栏。InvestorPlace所有板块 已经有相关报道。其中包括有关Peloton(纳斯达克股票代码:PTON)、Ardelyx(纳斯达克股票代码:ARDX)和Nvidia(纳斯达克股票代码:NVDA)的最新股票资讯。您可以在以下链接了解更多!

More Monday Stock Market News

更多周一股票市场资讯

  • PTON Stock: The UNH Deal Giving Peloton Shares a Jump Today
  • ARDX Stock: Disastrous FDA News Sends Ardelyx Shares Plummeting
  • Nvidia Stock Split 2021: What NVDA Investors Should Know as the 4-for-1 Split Goes Into Effect
  • PTON股票:联合健康交易让Peloton股票今天大涨
  • ARDX股票:灾难性的FDA新闻导致Ardelyx股票暴跌
  • 英伟达股票分拆2021年:NVDA投资者应该了解的4比1拆股生效

On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.

在发布日期,William White本文作者的观点,受 InvestorPlace.com 的约束。更新的临床和财务数据支持 CRISPR therapeutics 的立场出版指南.

With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this fact and warn readers of the risks. Read More: Penny Stocks — How to Profit Without Getting Scammed

除非特殊情况,InvestorPlace不会刊登市值低于10000万美元或每天交易不超过100,000股的公司的评论。这是因为这些“低价股”经常是骗子和市场操纵者的游乐场。如果我们确实发表了意见,可能会影响低交易量股票时,我们要求作者公开这个事实并警告读者注意风险。InvestorPlace.com阅读更多:便士股票—— 发帖烟草便士股Kaival Brands的8个要点,投资者要了解

The post NURO Stock: The ‘Breakthrough’ News Rocketing NeuroMetrix Shares Higher Today appeared first on InvestorPlace.

股票NURO:这一突破性资讯让neurometrix股价今日大涨

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发